Saturday 17 October 2026
Export ATXI’s income statement to Excel — free account
Avenue Therapeutics, Inc.
ATXI Healthcare Biotechnology
Avenue Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million. In the quarter to June 2026, EPS fell 290.9% and free cash flow fell 169.9%, each against the same quarter a year earlier.
0.43
0.00
0.00%
Follow ATXI
Avenue Therapeutics, Inc. (ATXI) P/E ratio
Avenue Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.2× (October 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 1.2×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| ATXI Avenue Therapeutics, Inc. | n/m |
| LYRA Lyra Therapeutics, Inc. compare | n/m |
| MNTRQ 9 Meters Biopharma, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | n/m |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)